NCT05987644 2026-03-09
DURABLE
Hoosier Cancer Research Network
Phase 1/2 Recruiting
Clinical Trials
16 trialsNCT04302025 2026-03-06
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
NCT04589845 2026-03-06
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Recruiting
NCT04774718 2026-03-06
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06765109 2026-02-17
ALKAZAR
Nuvalent Inc.
Phase 3 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT07001384 2025-08-14
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT05713006 2025-05-01
Alectinib Pharmacokinetic in Patients With NSCLC
Instituto Nacional de Cancerologia de Mexico
Phase 1/2 Recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04322890 2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05014464 2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05159245 2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2 Recruiting
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting